FDA Abandons Negotiations With Cosmetics Industry On Legislative Plan
This article was originally published in The Rose Sheet
Executive Summary
Negotiations between FDA and the cosmetics industry on a legislative plan to modernize regulatory oversight of cosmetics have come to a halt, with FDA Deputy Commissioner for Foods and Veterinary Medicine Michael Taylor asserting in a March 6 letter that there is no longer common ground between the groups. The Personal Care Products Council urges the agency to return to the table and work out an agreement.
You may also be interested in...
US FDA Wants Remote Regulatory Assessment Authority For Cosmetics – FY 2023 Budget Justification
After freezing its routine inspection activities at the height of the COVID-19 pandemic, the FDA adapted its oversight approach visibly in the drug and medical devices sectors, including with voluntary remote regulatory assessments. The agency now seeks authority to continue that work on a non-voluntary basis across all FDA-regulated programs.
PCPC, FDA Negotiate Oversight Bill With Possible State-Law Preemption
While acknowledging that there is “a long, long way to go,” PCPC’s John Hurson says industry and FDA have reached a tentative framework for legislation that would update federal cosmetics regulations and possibly preempt state laws, which have become the bane of national cosmetics manufacturers.
ICCS President Hill On Growing Regulatory Confidence In Alternative Testing Methodologies
In the year since its establishment, the International Collaboration on Cosmetics Safety has worked to engage with regulators as they build frameworks for assessing cosmetic safety without animal tests. ICCS president and CEO Erin Hill discusses current challenges and what lies ahead.